SCHEMBL19459115

SCHEMBL19459115

O=[C]c1ccc(C(=O)C(F)(F)F)cc1

nearest known ligand 0.56

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CES1 P23141 1/20 0.56
MLYCD O95822 16/20 0.51
TRPV1 Q8NER1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7368558 0.81 MLYCD (0.73) CES1MLYCD
SCHEMBL9359045 0.78 PGR (0.42) CES1MLYCD
SCHEMBL19056956 0.77 CES1 (0.65) CES1MLYCDTRPV1
SCHEMBL2174033 0.75 CES1 (0.62) CES1MLYCDTRPV1
SCHEMBL16823 0.75 CES1 (0.62) CES1MLYCDTRPV1
SCHEMBL1421656 0.75 CES1 (0.70) CES1MLYCD
SCHEMBL103281 0.75 CA1 (0.37) CES1
SCHEMBL11238566 0.74 SRD5A2 (0.50)
SCHEMBL28612795 0.74 PTPN1 (0.39) CES1
SCHEMBL8909202 0.74 CES1 (0.50) CES1MLYCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3442977-B1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORP (US) 2023-06-28 EP claimed
US-10669277-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2020-06-02 US claimed
US-20200031830-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION (US) 2020-01-30 US claimed
CN-103063724-B Solid carbonate ion electrode based on conductive polyaniline and preparing method thereof UNIV ZHEJIANG 2014-12-10 CN claimed
CN-103063724-A Solid carbonate ion electrode based on conductive polyaniline and preparing method thereof UNIV ZHEJIANG 2013-04-24 CN claimed
US-20240158398-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION 2024-05-16 US disclosed
EP-4285996-A2 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE Blueprint Medicines Corporation (US) 2023-12-06 EP disclosed
EP-3442977-B1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORP (US) 2023-06-28 EP disclosed
US-11634422-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2023-04-25 US disclosed
US-10669277-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2020-06-02 US disclosed
US-20200031830-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION (US) 2020-01-30 US disclosed
US-10233186-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2019-03-19 US disclosed
EP-3442977-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE Blueprint Medicines Corporation (US) 2019-02-20 EP disclosed
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION 2017-10-19 US disclosed
WO-2017181117-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION (US) 2017-10-19 WO disclosed
CN-103063724-B Solid carbonate ion electrode based on conductive polyaniline and preparing method thereof UNIV ZHEJIANG 2014-12-10 CN disclosed
CN-103063724-A Solid carbonate ion electrode based on conductive polyaniline and preparing method thereof UNIV ZHEJIANG 2013-04-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10669277-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 CES1 2763/4885MLYCD 2507/4885TRPV1 4333/4885
US-20240158398-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE ACVR1, ACVR2A, ACVRL1 CES1 2763/4885MLYCD 2507/4885TRPV1 4333/4885
US-20200031830-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE ACVR1, ACVR2A, ACVRL1 CES1 2763/4885MLYCD 2507/4885TRPV1 4333/4885
US-11634422-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 CES1 2763/4885MLYCD 2507/4885TRPV1 4333/4885
US-10233186-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 CES1 2592/4885MLYCD 3044/4885TRPV1 3932/4885
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE ACVR1, ACVR2A, ACVRL1 CES1 2763/4885MLYCD 2507/4885TRPV1 4333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.